Biological E gets $200 million vaccine supply contract from Egypt
The firm will supply 8 million doses of liquid pentavalent each year to an Egyptian firm
Hyderabad: Vaccine maker Biological E Ltd on Thursday said it has entered into a 10-year supply agreement worth $200 million (around ₹ 1,200 crore ) with Vacsera, an Egyptian state-owned vaccine company, to supply 8 million doses of liquid pentavalent each year.
Pentavalent is a combination paediatric vaccine, that immunizes children against diphtheria, pertussis, tetanus, hepatitis-B and HiB.
“Under the agreement, Biological E’s pentavalent vaccine shall be procured exclusively by Vacsera," Biological E statement said.
“The deal can be extended further post mutual discussion and agreement," the company said.
Biological E’s Liquid Pentavalent vaccine was prequalified by WHO (World Health Organization) in 2012 and has been exported to several countries.
The company has recently entered into a five-year supply arrangement with Global Alliance for Vaccination and Immunization for its inactivated polio virus containing hexavalent vaccine under development with GlaxoSmithKline Plc.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!